BioSpace

The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco. There was an air of hope and optimism concerning biopharma funding - but will it last? Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive AI ⁠ is still a hot topic including generative AI ; M&A and VC funding; and general whiffs of cautious optimism. Join Lori, Greg and Tyler as they discuss what's been top of mind today. You can ⁠⁠⁠follow our coverage⁠⁠⁠ as our team adds updates thro...

Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: AI , cell and gene therapy innovation and pricing, and the risks of CAR T cell therapy. Join Lori, Greg and Tyler as they discuss what's been top of mind. You can ⁠⁠follow our coverage⁠⁠ as our team adds updates throughout the day. Join us tomorrow...

Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one. Join Lori, Greg and Tyler as they discuss what's moving and shaking. You can ⁠follow our coverage⁠ as our team adds updates throughout the day. Get Greg's take on ⁠what this year might hold⁠ in store and how the Biden administration's policies may ⁠play a role in discussions⁠ . Joi...

The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in 2024? Listen to this discussion on different kinds...

Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S.  NextGen Class of 2024 ⁠ includes organizations that launched between September 2022 and September 2023 with a Series A funding .  BioSpace's Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss.

How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding. Host  ⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠ , Head of Insights, BioSpace    Guests ⁠Ansbert Gadicke⁠ , Managing Director, MPM Capital ⁠Martin Gersh...

Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhile Sanofi throws in towel over threat of injunction  Renewed interest in psychedelics after MindMed’s Phase IIb trial of its LSD-based candidate meets primary endpoint in patients with generalized anxiety disorder.   Bluebird bio changes its tune, sig...

What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen.  Host  ⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠ , Head of Insights, BioSpace    Host  ⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠ , Head of Insights, BioSpace    Guests ⁠⁠Ansbert Gadicke⁠⁠ , Managing Director, MP...

That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing therapy from Vertex and CRISPR Therapeutics, and bluebird bio’s Lyfgenia , which comes with a hefty price tag and a black box warning.  Axcella announced its closure; what does the future of long-covid treatments look like, especially as attention shift...

This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and IQVIA. We dive into regulation, real-time management, and AI's various applications and how it can streamline different processes. We also discuss the cost and affordability of AI; the tremendous investment required and when holding off on new tech is...

Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is happening now in healthcare and life sciences. Hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks.  Host  ⁠⁠⁠Lori Ellis⁠⁠⁠ , Head of Insights,...

The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum c...

Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with patients to optimize and grow data pools? This is the third and final part of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Host  ⁠⁠Lori Ellis⁠⁠ , Head...

The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety? Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction. This is part two of a discussion focused upon data bias, accuracy,...

This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠Dupixent⁠⁠ in COPD. Plus, Merck buys Caraway , Beigene's deal with Ensem, ups and downs for Flagship. Join BioSpace's Lori Ellis , Greg Slabodkin and Tyler Patchen as they discuss the most important biopharma news this week.

Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA)  approved CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can patients expect the price tag to be? Plus, a good handful of approvals for AstraZeneca , Pfizer and Astellas' Xtandi , and Keytruda. Join BioSpace's Lori Ellis , Greg Slabodkin and Heather McKenzie as t...

This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise. Host  Lori Ellis , Head of Insights, BioSpace     Guests  Paul Agapow , Director of Innovation, Data Science and Strategy, GlaxoSmithKline Mike King , Senior Director of Product and Stra...

Last week, the FDA approved Eli Lilly's obesity drug Zepbound , creating an anticipated intense competition between it and Novo Nordisk's Wegovy . BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class. Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval .

This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more. Want to dive deeper on BioSpace? Read more on Pfizer's recent cuts⁠ as part of their cost-savings program and more insight on Q3 earnings for Gilead ,  ⁠⁠Novo Nordisk,...